--- title: "TriMas (TRS) Could Be 12% Undervalued Following Raised Earnings Guidance" type: "News" locale: "en" url: "https://longbridge.com/en/news/296887641.md" description: "TriMas (TRS) raised its full-year adjusted earnings guidance, citing sales growth and margin improvement. While a narrative suggests the stock is ~12% undervalued at $39.57 against a fair value of $45 due to automation and e-commerce tailwinds, an SWS DCF model values shares at $4.52, indicating it may be expensive. Risks include integration challenges and cyclical demand exposure." datetime: "2026-08-25T09:20:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296887641.md) - [en](https://longbridge.com/en/news/296887641.md) - [zh-HK](https://longbridge.com/zh-HK/news/296887641.md) generator: "portal-rs" --- # TriMas (TRS) Could Be 12% Undervalued Following Raised Earnings Guidance TriMas (TRS) drew fresh attention after raising the low end of its full year adjusted earnings guidance while reiterating expectations for sales growth and margin improvement, a combination that has supported a more constructive tone around the stock. See our latest analysis for TriMas. At a share price of US$39.57, TriMas has seen a modest gain over the past week, while the 30 day and 90 day share price returns show some recent softness despite a positive 9.04% year to date share price return and a 3 year total shareholder return of 55.52% that underscores how sentiment has improved over a longer period. If TriMas raising guidance has you thinking about where else the market may be reassessing quality, it can be worth scanning 20 top founder-led companies TriMas appears to be a stronger business today after its guidance move, but strength on paper is only half the story. Is the current share price offering a fair entry into that progress, or is it asking too much for it? ## Most Popular Narrative: 12.1% Undervalued TriMas is trading at $39.57 compared with a widely followed fair value narrative of $45. This gap reflects a view that the current price does not fully reflect the company’s longer term earnings potential. > *Increased investment in automation, advanced IT platforms, and operational best practices is expected to unlock cost efficiencies and productivity gains across all business segments, contributing to sustainable improvements in EBITDA margin and overall profitability. Robust global trends such as rising e commerce activity and growing demand for health, hygiene, and safety packaging are providing durable tailwinds for TriMas' packaging and dispensing businesses, underpinning long term revenue growth and supporting higher future earnings.* Read the complete narrative. Want to understand why this narrative supports a higher value for TriMas? The story leans heavily on improving margins, steadier revenue growth, and a future profit multiple that assumes investors keep paying up for those stronger earnings. **Result: Fair Value of $45 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear risks to the TriMas story, including ongoing integration challenges in Packaging and exposure to cyclical aerospace and industrial demand that could pressure margins. Find out about the key risks to this TriMas narrative. ## Another View on TriMas: What The Market Multiple Is Saying The SWS DCF model points to a future cash flow value of $4.52 per TriMas share, far below the current $39.57 price. That implies the stock screens as expensive on this method, in sharp contrast to the 12.1% undervalued fair value narrative. Which lens do you trust more for your own work? Look into how the SWS DCF model arrives at its fair value. TRS Discounted Cash Flow as at Aug 2026 ## Next Steps If this mix of optimism and concern around TriMas feels familiar, consider reviewing the underlying data for yourself and weighing both sides of the story using 3 key rewards and 1 important warning sign ## Looking for more investment ideas beyond TriMas? If TriMas has sharpened your interest in quality opportunities, do not stop here. Broaden your watchlist and give yourself more options before the market moves on. - Zero in on quality at a discount by scanning companies that look attractively priced using the 49 high quality undervalued stocks. - Build a steadier income stream by reviewing stocks highlighted in the 12 dividend fortresses. - Limit downside risk while still staying invested by checking companies identified in the 74 resilient stocks with low risk scores. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if TriMas might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [TRS.US](https://longbridge.com/en/quote/TRS.US.md) ## Related News & Research - [45,318 Shares in TriMas Corporation $TRS Bought by Ancora Advisors LLC](https://longbridge.com/en/news/297139938.md) - [TriMas Publishes 2025 Sustainability Report | TRS Stock News](https://longbridge.com/en/news/294852761.md) - [Lowe's Stock: Is LOW Underperforming the Consumer Cyclical Sector?](https://longbridge.com/en/news/297643702.md) - [Analysts Offer Insights on Consumer Cyclical Companies: Five Below (FIVE) and Ermenegildo Zegna (ZGN)](https://longbridge.com/en/news/298143996.md) - [Walmart (WMT) Stock Seems Fairly Priced After Its $1.3B Automation Push](https://longbridge.com/en/news/298123093.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**